A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva

Tanima Bose¹, Aihua Hou², Ryan Lee³, Louis Tong²,³,⁴,⁵, K. George Chandy¹
¹Lee Kong Chian School of Medicine, Nanyang Technological University
²Singapore Eye Research Institute
³Singapore National Eye Center
⁴Duke-NUS Medical School
⁵Yong Loo Lin School of Medicine

Correspondence to: Louis Tong at louis.tong.h.t@singhealth.com.sg, K. George Chandy at gchandy@ntu.edu.sg

URL: https://www.jove.com/video/55591
DOI: doi:10.3791/55591

Keywords: Immunology, Issue 125, Impression cytology, dry eye disease, impression cytology device, effector memory T cells, central memory T cells, terminally differentiated effector memory T cells, HLA-DR, ocular surface impression cytology, flow cytometry

Date Published: 7/5/2017

Abstract

Traditionally, ocular surface cytology is studied with techniques such as spatula technology and brush technology. The problem with these techniques is that they may induce traumatic lesions on the surface of the eye, which can progress to scarring, eyelid deformity, limbal stem cell deficiency and in some cases, cause great discomfort to the subject. To avoid these clinical problems, impression cytology (IC) was developed to diagnose dry eye disease and later neoplasia, atopic disease, vernal keratoconjunctivitis and keratoconjunctivitis sicca. Typically, clinicians manually cut filter papers into required shapes and apply these to the ocular surface. Here, we describe how to perform IC using a commercially available medical device. This technique is explained here followed by immunophenotyping by flow cytometry. This technique requires less manual handling and causes less injury to the ocular surface.

Video Article

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva

Introduction

Impression cytology (IC) was first performed in 1977 by Thatcher et al.¹. They used a plastic impression disc to collect conjunctival cells from patients instead of other techniques available at that time such as scraping, swabbing or pipetting¹. The current technique of IC uses an absorbent filter paper² to imprint the bulbar and palpebral conjunctiva and collect the most superficial layer of conjunctival cells. These cells, having reached their final stage of differentiation, are continuously shed into tears³. Three major populations of cells are found in IC specimens: epithelial cells⁴, goblet cells⁵, and mucosal-associated lymphoid tissue viz epithelium-associated effector T cells or dendritic cells⁶. Ocular surface cells in IC samples can be analyzed by microscopy, immune-blotting and reverse-transcriptase polymerase chain reaction (RT-PCR)⁷. Flow cytometry has been recently used to analyze immune cells collected by scraping the IC membrane⁸. Interestingly, IC⁹,¹⁰ has been used to evaluate many ocular surface diseases including keratoconjunctivitis sicca, vitamin A deficiency, cicatrical pemphigoid, atopic disease, superior limbic keratoconjunctivitis, vernal keratoconjunctivitis, and epithelial squamous metaplasia. IC has also been used to evaluate the impact of wearing contact lenses, detecting ocular surface microbes, and testing therapeutic efficacy and tolerance of therapeutic interventions in longitudinal studies¹⁰,¹¹,¹².

The medical device (EyePrim) is supported by a type of polyethersulfone (PES) 0.2-µm membrane, which has been previously validated for the technique of ocular impression cytology with flow cytometry (OSIC-flow) and opens up opportunities to use longitudinal sampling to monitor disease progression and response to treatment (e.g., the detailed analysis of intraepithelial leukocytes defined as putative disease markers for progressive conjunctival fibrosis in mucous membrane pemphigoid)¹³. Early researchers used autoclaved PES filters that required manual impression. As a result, the yield was variable and user dependent. The advantage of this medical device is ease of use, standardized pressure (Pa or N/m²), and enables repeatability, reproducibility, and consistent cellular recovery. This technique is useful in an out-patient clinic because it is non-surgical, easy-to-perform and rapid. This is a Class I (sterile) medical device according to the directive 93/42/CEE, CE 0499 (SNCH). It only requires topical anesthesia during the procedure, which ensures maintenance of the integrity of the ocular surface. Following IC, cells can be processed immediately for flow cytometry.

Despite the improvement of IC over other techniques, several challenges remain. For example, there may be variation due to the area of the sampling and regional differences in the bulbar conjunctiva depending on the position of the IC. Another source of variation is due to the application of different amounts of pressure during IC. Other methodological issues involve standardization of cell processing: these involve duration and method of fixation, and the conditions of possible storage, which may impact stability of the sampled material.
1. **Collection of Ocular Samples by IC**

1. **NOTE:** Subjects underwent clinical tests to assess the extent of inflammation and the severity of tear dysfunction before IC was performed. Clinical tests included non-invasive tear break-up time (NI-TBUT)\textsuperscript{14} and conjunctival redness (hyperemia)\textsuperscript{15,16} assessed with a diagnostic instrument, Schirmer's test\textsuperscript{17}, Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire\textsuperscript{18}, and corneal staining\textsuperscript{19}.

2. Centrifuge the cells at 400 x g for 5 min at room temperature to remove the media. Resuspend the cell pellet with 50 µL of flow cytometry staining buffer (phosphate buffered saline (PBS) + 0.05% bovine serum albumin (BSA)).

3. Stain cells with a panel of antibodies (e.g., CD3 brilliant violet (BV) 510 (UCHT1), CD4 allophycocyanine-H7 (APC-H7) (SK3), CCR7 phycoerythrin (PE)-A, CD45RO PE-cyanin 7 (PE-Cy7)-A, and live/dead cell mark 7-ADD) at room temperature for 20 - 30 min in the dark. Use antibodies directly from the stock according to the manufacturer's protocol.

**NOTE:** For the antibody concentration, use 2.5 µL of CD3-BV510, 1.25 µL of CD4-APC-H7, CD45RO-PE-Cy7, 7-AAD and 10 µL of phycoerythrin (PE)-A, CD45RO PE-cyanin 7 (PE-Cy7)-A, and live/dead cell mark 7-ADD.

4. Isolate cells from the membrane of the device by continuous scraping for around 1 min with a 10 µL pipette tip.

**NOTE:** The scraping is completed when the surface of the membrane becomes uneven. The cell numbers from each membrane is variable (100 - 500 cells/membrane). Process the samples within 2 - 3 h of collection.

2. **Immunophenotyping Cells by Flow Cytometry**

1. **NOTE:** Isolated cells must be applied to the immunological characterization of the clinical samples.

2. **NOTE:** Before acquiring the data, calibrate the flow cytometer channel voltages with cytometer setup and tracking (CS&T) beads to normalize the data acquisition on different days as per manufacturer's instructions.

3. **NOTE:** After acquiring 10,000 events per sample.

4. **NOTE:** Acquire 10,000 events per sample.

1. Before acquiring the data, calibrate the flow cytometry channel voltages with cytometer setup and tracking (CS&T) beads to normalize the data acquisition on different days as per manufacturer's instructions.

   1. Open the flow cytometry data collection software, click "Set up & QC" button, choose the correct CS&T bead lot number, load the beads, and then click the "Start" button.

2. Resuspend cells by gently tapping the tube before loading samples to the machine. Open the data collection software and click "Preview". When threshold rate is stable, click "Acquire". Monitor the sample level and click "Stop" when samples run out.

3. After the incubation period, add 1 mL of staining buffer to the tube, mix well, and centrifuge at 450 x g for 5 min at room temperature. Resuspend cells in 200 µL of staining buffer.

4. Run samples on a flow cytometry machine.

   1. **NOTE:** After acquiring 10,000 events, generate a SSC-A and FSC-A dot plot in the worksheet.

   2. **NOTE:** Acquire 10,000 events per sample.

   3. After acquiring 10,000 events, generate a SSC-A and FSC-A dot plot in the worksheet.

   4. **NOTE:** Acquire 10,000 events per sample.

   5. After acquiring 10,000 events, generate a SSC-A and FSC-A dot plot in the worksheet.

   6. **NOTE:** Acquire 10,000 events per sample.

   7. After acquiring 10,000 events, generate a SSC-A and FSC-A dot plot in the worksheet.

   8. **NOTE:** Acquire 10,000 events per sample.

   9. After acquiring 10,000 events, generate a SSC-A and FSC-A dot plot in the worksheet.

   10. **NOTE:** Acquire 10,000 events per sample.
NOTE: Upper left hand side, upper right hand side, lower right hand side and lower left hand side quadrants here are naïve, central memory (T_{CM}), effector memory (T_{EM}), terminally differentiated effector memory (T_{EMRA}) T cells, respectively.

Representative Results

IC by this clinical device allowed us to isolate ocular surface immune cells while keeping the ocular surface intact. Figure 1 describes how the IC was performed. The different sites of the eye from where the samples were collected are marked. Figure 2 shows representative result of flow cytometry collected from 10 healthy controls. For the gating, use SSC and 7-AAD to distinguish between live and dead cells. 7-AAD- cells are identified as live cells. These live cells are further characterized by CD3+ and CD4- markers. Furthermore, the CD4+ and CD4- populations were each further characterized as Naïve, T_{EM}, T_{CM} and T_{EMRA} with the CCR7 and CD45RO markers. Amongst CD3+ T cells, effector memory T cells predominate in the human ocular surface. In earlier experiments, it has also been shown that CD8+ memory cells are the major populations in the conjunctival epithelial T cells among the healthy individuals\(^2\). Figure 3 shows that CD4+ and CD8+ effector memory T cells (T_{EM} and T_{EMRA}) are the major subset in the human ocular surface in 10 healthy controls studied. Each population mentioned in the figure are notified with their marker phenotype and names (Naïve, T_{CM}, T_{EM}, T_{EMRA}). The numbers in red denote the percentage of the population. The data in this figure are represented as mean ± SEM.

Impression cytology

Figure 1: Collection of IC Samples from the Ocular Surface by the Impression Cytology Device. Samples were collected from the temporal bulbar region as shown.

Figure 2: Dot Plot Graph using Flow Cytometry. Live 7-AAD- cells were selected. The CD3+ cells were first gated, and then this population was gated into CD4+ and CD4- subsets. The proportions of naïve (CCR7CD45RO+), central memory (CCR7CD45RO+) and effector memory (CCR7CD45RO+, CCR7CD45RO-) subsets was determined with the help of CCR7 and CD45RO markers. Please click here to view a larger version of this figure.
Figure 3: Immune Cell Sub-types in CD4+ and CD8+ T Cells of Healthy Human Ocular Surface. Distribution of conjunctival CD4+ and CD8+ naive, central memory (T_{CM}), and effector memory (T_{EM} and T_{EMRA}) subsets in healthy human controls; each data point represents a separate individual mean ± SEM shown. The percentage of the population is marked as red below the name of each of the populations. The total percentage of the population is 98%, because CD4+ T_{EMRA} population was not included in the mentioned scatterplot (modified from Bose et al.21). Please click here to view a larger version of this figure.

Discussion

This is an easy, quick and less invasive technique that can be used in the out-patient clinics for relatively fast immune profiling in contrast to the conventional techniques like scraping, swabbing, pipetting or absorbent filter paper1,2. A variant of this technique is already being used in research settings22. The future application of the proposed methodology is for patient stratification in clinical trials with ocular diseases, especially those requiring immunophenotyping.

A major challenge with this technique is the relatively few immune cells retrieved after impression collection and scraping. The total number of CD3+ T cells recovered from four impressions per individual varied from ~ 500 - 1,000 cells. The ocular samples were washed before the flow cytometry analysis for a minimal number of times to avoid further loss of cells. Critical steps and challenges that remain within the protocol are efficient collection of ocular samples and proper scraping of the membrane to achieve higher cell numbers. Nevertheless, this limitation is unlikely to bias towards any specific immune phenotype. The troubleshooting performed here to maximize the yield of cells was to reduce the number of washing steps after and before the incubation of antibodies.

There are other limitations to using IC. In patients with severely keratinized or fibrosed ocular surface such as in Steven Johnson syndrome, the cellular yield may be even less than that in this study. The proportion of immune cells may change if the samples are stored instead of analyzed on the same day. It is difficult to predict if certain cell types are more resistant to storage than others. Previous studies have reported elevated levels of HLA-DR expression in the conjunctival epithelial cells23, so it would be interesting to evaluate the correlation between HLA-DR and levels of specific immune cells. Immune cells may also be associated with the expression level of chemokines. These issues should be addressed in future studies.

Disclosures

The authors declare no competing financial interests.

Acknowledgements

The authors would like to thank Nandini Nallappan and Sharon Yeo for helping with the technical steps. The study was funded by a Start-Up Grant to KGC from Lee Kong Chian School of Medicine, Nanyang Technological University and by a Senior Clinician Scientist Award from the Singapore Ministry of Health’s National Medical Research Council (NMRC) to LT (NMRC/ CSA/ 045/ 2012) and by a grant from the NMRC and administered by the National Health Innovation Centre to KGC and LT (NHIC-12D-1409007).
References


22. Williams, G. P., et al. The dominant human conjunctival epithelial CD8alphabeta+ T cell population is maintained with age but the number of CD4+ T cells increases. *Age (Dordr).* **34**(6), 1517-1528 (2012).